The prevalence of trapeziometacarpal (TMC) osteoarthritis (OA) is 13% in the under 50 years old population [1].

Management of TMC OA initially consists of conservative medical treatment involving painkillers, anti-inflammatory drugs, orthoses and steroid infiltration [2,3]. The goal is to relieve as much pain as possible to improve function.

When conservative treatment fails surgery may be discussed. Numerous surgical techniques have been described for the treatment of this OA (osteotomies, trapeziectomy, interposition arthroplasty, TMC prosthesis, etc.), but there is no consensus in the literature for the treatment of young patients after failure of a well-managed medical treatment [4].

Pyrocardan® implant was proposed for the treatment of TMC OA [[5], [6], [7]]. This implant has been shown to be a valid medium- and long-term solution for patients aged over 60 years old [[8], [9], [10], [11]].

This study aimed to evaluate the clinical, functional, and radiological results in patients under 50 years old who were treated with a Pyrocardan® implant for their TMC OA.

The hypothesis was that the Pyrocardan® implant could be an effective treatment option for patients aged 50 years and younger.